Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
polymyalgia rheumatica epidemiology forecast insight

SALE

Polymyalgia Rheumatica -Epidemiology Forecast -2034

Published Date : 2025

Pages : 56

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

polymyalgia rheumatica epidemiology forecast insight

DelveInsight’s ‘Polymyalgia Rheumatica (PMR)–Epidemiology Forecast—2034’ report delivers an in-depth understanding of the Polymyalgia Rheumatica (PMR), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2021-2034

Polymyalgia Rheumatica (PMR) Disease Understanding

Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic condition in people aged over 50 years after rheumatoid arthritis (RA). PMR can occur independently or in association with giant cell arteritis (GCA). Giant cell arteritis is the most common primary vasculitis in this age group.

PMR is a rare inflammatory disease characterized by muscle pain (myalgia), stiffness, and additional generalized systemic symptoms such as fatigue, low-grade fever, and/or a general feeling of ill health (malaise). It can be a relatively benign condition that is extremely responsive to treatment. In some rare cases, permanent muscle weakness, degeneration and loss (atrophy) of muscle mass, and disability may occur.

The cause of PMR is uncertain, but it is believed to be an autoimmune disease in which the body’s immune system attacks healthy tissues. Genetic and environmental factors (such as infections) are thought to play important roles. Because it is rare in people under age 50, its cause could be linked to the aging process.

The diagnosis of PMR may be confirmed by a thorough clinical examination, including detailed patient history and specialized blood testing that demonstrates an abnormally elevated sedimentation rate. Other substances in the blood, such as serum albumin, globulins, and fibrinogen, may also be elevated.

PMR treatment focuses on reducing pain and inflammation and easing stiffness, achiness, fatigue, and fever. Treatment includes anti-inflammatory medication and exercise. Corticosteroids are powerful anti-inflammatory drugs that help reduce inflammation and relieve stiffness and pain. They are the mainstay of PMR treatment. The dosage for PMR is low, and symptoms will improve quickly with treatment. The dosage will be lowered further once symptoms improve. Occasionally, mild PMR cases are treated with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, to ease symptoms.

Both exercise and rest play important roles in PMR treatment. Regular exercise is essential for maintaining joint flexibility, muscle strength, and function. Good forms of exercise include walking, riding a stationary bicycle, and exercising in a pool.

Polymyalgia Rheumatica (PMR) Epidemiology

The Polymyalgia Rheumatica (PMR) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Polymyalgia Rheumatica (PMR) epidemiology segmented as the Prevalence of Polymyalgia Rheumatica (PMR), Prevalence of Polymyalgia Rheumatica (PMR) based on Clinical Manifestation, Gender-specific cases of Polymyalgia Rheumatica (PMR), Diagnosed cases GCA in PMR. The report includes the Prevalent scenario of Polymyalgia Rheumatica (PMR) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise- Polymyalgia Rheumatica (PMR) Epidemiology

The epidemiology segment also provides the Polymyalgia Rheumatica (PMR) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Polymyalgia Rheumatica (PMR) Associated in 7MM countries was estimated to be 1,708,823 cases in 2020 and expected to increase at a CAGR of 0.78% for the study period, i.e., 2021-2034.

As per the estimates, United States has the highest prevalent population of Polymyalgia Rheumatica (PMR) in 7MM.
Among the EU5 countries, France had the highest prevalent population of Polymyalgia Rheumatica (PMR). On the other hand, Spain had the lowest number of cases, 117,019 cases in 2020.

Scope of the Report

Polymyalgia Rheumatica (PMR) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
Polymyalgia Rheumatica (PMR) Epidemiology Report and Model provide an overview of the risk factors and global trends of Polymyalgia Rheumatica (PMR) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Polymyalgia Rheumatica (PMR) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps recognize the growth opportunities in the 7MM concerning the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Polymyalgia Rheumatica (PMR)
The report provides the segmentation of the Polymyalgia Rheumatica (PMR) epidemiology by prevalent Cases of Polymyalgia Rheumatica (PMR) in 7MM
The report provides the segmentation of the Polymyalgia Rheumatica (PMR) epidemiology by Prevalence of Polymyalgia Rheumatica (PMR), Prevalence of Polymyalgia Rheumatica (PMR) based on Clinical Manifestation, Gender-specific cases of Polymyalgia Rheumatica (PMR), Diagnosed cases GCA in PMR in 7MM

Report Highlights

10-year Forecast of Polymyalgia Rheumatica (PMR) epidemiology
7MM Coverage
Total Prevalent Cases of Polymyalgia Rheumatica (PMR)
Prevalence of Polymyalgia Rheumatica (PMR) based on clinical manifestation
Gender-specific Cases of Polymyalgia Rheumatica (PMR)
Diagnosed cases of GCA in PMR

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

What will be the growth opportunities in the 7MM concerning the patient population about Polymyalgia Rheumatica (PMR)?
What are the key findings of Polymyalgia Rheumatica (PMR) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2025-2034)?
What would be the total number of patients with Polymyalgia Rheumatica (PMR) across the 7MM during the forecast period (2025-2034)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2025-2034)?
At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?
What are the disease risk, burden, and unmet needs of Polymyalgia Rheumatica (PMR)?
What are the currently available treatments for Polymyalgia Rheumatica (PMR)?

Reasons to buy

The Polymyalgia Rheumatica (PMR) Epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global Polymyalgia Rheumatica (PMR) market
Quantify patient populations in the global Polymyalgia Rheumatica (PMR) market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Polymyalgia Rheumatica (PMR) therapeutics in each of the markets covered
Understand the magnitude of Polymyalgia Rheumatica (PMR) population by its prevalent cases
Understand the magnitude of Polymyalgia Rheumatica (PMR) population by its clinical manifestation specific cases
The Polymyalgia Rheumatica (PMR) epidemiology report and model was written and developed by Masters and PhD level epidemiologists
The Polymyalgia Rheumatica (PMR) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

List of Tables:

List of Table

Table 1: Summary of PMR, Market, Epidemiology, and Key Events (2021-2034)

Table 2: Summary of classification criteria for polymyalgia rheumatica (PMR)

Table 3: PMR classification criteria scoring algorithm by EULAR/ACR

Table 4: Total Diagnosed Prevalent Patient Population of Polymyalgia Rheumatica in 7MM in 000’s (2021-2034)

Table 5: Prevalence of Polymyalgia Rheumatica in the United States (2021-2034)

Table 6: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United States (2021-2034)

Table 7: Gender-specific Prevalence of Polymyalgia Rheumatic in the United States (2021-2034)

Table 8: Diagnosed Cases of GCA in PMR in the United States (2021-2034)

Table 9: Prevalence of Polymyalgia Rheumatica in Germany (2021-2034)

Table 10: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Germany (2021-2034)

Table 11: Gender-specific Prevalence of Polymyalgia Rheumatic in Germany (2021-2034)

Table 12: Diagnosed Cases of GCA in PMR in Germany (2021-2034)

Table 13: Prevalence of Polymyalgia Rheumatica in (2021-2034)

Table 14: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in France (2021-2034)

Table 15: Gender-specific Prevalence of Polymyalgia Rheumatic in France (2021-2034)

Table 16: Diagnosed Cases of GCA in PMR in France (2021-2034)

Table 17: Prevalence of Polymyalgia Rheumatica in Italy (2021-2034)

Table 18: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Italy (2021-2034)

Table 19: Gender-specific Prevalence of Polymyalgia Rheumatic in Italy (2021-2034)

Table 20: Diagnosed Cases of GCA in PMR in Italy (2021-2034)

Table 21: Prevalence of Polymyalgia Rheumatica in Spain (2021-2034)

Table 22: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Spain (2021-2034)

Table 23: Gender-specific Prevalence of Polymyalgia Rheumatic in Spain (2021-2034)

Table 24: Diagnosed Cases of GCA in PMR in Spain (2021-2034)

Table 25: Prevalence of Polymyalgia Rheumatica in the United Kingdom (2021-2034)

Table 26: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United Kingdom (2021-2034)

Table 27: Gender-specific Prevalence of Polymyalgia Rheumatic in the United Kingdom (2021-2034)

Table 28: Diagnosed Cases of GCA in PMR in the United Kingdom (2021-2034)

Table 29: Prevalence of Polymyalgia Rheumatica in Japan (2021-2034)

Table 30: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Japan (2021-2034)

Table 31: Gender-specific Prevalence of Polymyalgia Rheumatic in Japan (2021-2034)

Table 32: Diagnosed Cases of GCA in PMR in Japan (2021-2034)

Table 33: Organizations contributing toward Polymyalgia Rheumatica

List of Figures:

List of Figures

Figure 1: Pathogenic mechanisms in polymyalgia rheumatica (PMR)

Figure 2: Distribution of symptoms

Figure 3: Algorithm based on the 2015 EULAR/ACR recommendations for the management of polymyalgia rheumatica (PMR)

Figure 4: Total Diagnosed Prevalent Population of Polymyalgia Rheumatica in 7MM (2021-2034)

Figure 5: Prevalence of Polymyalgia Rheumatica in the United States (2021-2034)

Figure 6: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United States (2021-2034)

Figure 7: Gender-specific Prevalence of Polymyalgia Rheumatic in the United States (2021-2034)

Figure 8: Diagnosed Cases of GCA in PMR in the United States (2021-2034)

Figure 9: Prevalence of Polymyalgia Rheumatica in Germany (2021-2034)

Figure 10: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Germany (2021-2034)

Figure 11: Gender-specific Prevalence of Polymyalgia Rheumatic in Germany (2021-2034)

Figure 12: Diagnosed Cases of GCA in PMR in Germany (2021-2034)

Figure 13: Prevalence of Polymyalgia Rheumatica in France (2021-2034)

Figure 14: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in France (2021-2034)

Figure 15: Gender-specific Prevalence of Polymyalgia Rheumatic in France (2021-2034)

Figure 16: Diagnosed Cases of GCA in PMR in France (2021-2034)

Figure 17: Prevalence of Polymyalgia Rheumatica in Italy (2021-2034)

Figure 18: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Italy (2021-2034)

Figure 19: Gender-specific Prevalence of Polymyalgia Rheumatic in Italy (2021-2034)

Figure 20: Diagnosed Cases of GCA in PMR in Italy (2021-2034)

Figure 21: Prevalence of Polymyalgia Rheumatica in Spain (2021-2034)

Figure 22: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Spain (2021-2034)

Figure 23: Gender-specific Prevalence of Polymyalgia Rheumatic in Spain (2021-2034)

Figure 24: Diagnosed Cases of GCA in PMR in Spain (2021-2034)

Figure 25: Prevalence of Polymyalgia Rheumatica in the United Kingdom (2021-2034)

Figure 26: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United Kingdom (2021-2034)

Figure 27: Gender-specific Prevalence of Polymyalgia Rheumatic in the United Kingdom (2021-2034)

Figure 28: Diagnosed Cases of GCA in PMR in the United Kingdom (2021-2034)

Figure 29: Prevalence of Polymyalgia Rheumatica in Japan (2021-2034)

Figure 30: Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Japan (2021-2034)

Figure 31: Gender-specific Prevalence of Polymyalgia Rheumatic in Japan (2021-2034)

Figure 32: Diagnosed Cases of GCA in PMR in Japan (2021-2034)

Tags:

License Type

Offer